The company's peptide drugs are designed to eliminate cancer-specific tumor cells, allowing clinicians to begin treatment more quickly and increasing the likelihood of successful treatment. The drugs are based on an original discovery by Prof. Marit Otterlei and co-inventors at the Department of Cancer Research and Molecular Medicine at NTNU in Norway.